FAST NEWS: CStone drug approved for treatment of advanced non-small cell lung cancer
The Latest: Drug maker CStone Pharmaceuticals (2616.HK) announced on Tuesday its Pralsetinib, also known by the brand name Gavreto, was approved by China’s drug regulator as a first-line treatment for…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
